Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03905356
Other study ID # STUDY00010618
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date February 12, 2020
Est. completion date January 31, 2023

Study information

Verified date May 2023
Source Milton S. Hershey Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate exercise therapy as a method for potentially improving radiation therapy treatment toxicities for metastatic cancer patients receiving radiation therapy.


Description:

Study Objectives and Endpoints: Aim 1. To determine the acceptability, feasibility, and safety of an exercise intervention among cancer patients receiving radiation therapy. The investigators anticipate that >25% of approached patients will consent to the protocol; >33% of eligible radiation therapy patients who consent will perform the exercise prescribed (based on the response rate from EnACT); and <25% of participants will experience a musculoskeletal impairment (without treatment alterations) and <5% will experience a musculoskeletal injury with symptoms lasting ≥ week or requiring medical attention. The investigators' approach will be to include patients receiving definitive RT; excluding patients at high risk for side effects from combination therapy, including fracture or cardiovascular events. Aim 2. To discern the clinical outcomes of patients receiving RT+ET. The hypothesis is that adding ET to RT will improve patient reported outcomes and physical functioning. The investigators' approach will be to use standardized questionnaires and assessment tools: patient reported outcomes will be assessed using Common Terminology Criteria for Adverse Events - Patient Reported Outcomes (CTCAE-PROs), loaded onto tablets that patients use in the clinic. Questions will assess global PROs relevant to the ability to tolerate RT, including fatigue, pain, nausea, vomiting; and disease-site-specific PROs, including genitourinary/sexual symptoms for patients receiving pelvic RT. RT dose alterations will be documented. Scores will be compared pre- vs post- RT. The investigators will also use standardized measures already used in EnACT, including grip strength, 30-second chair stand, timed up-and-go, and 4-stage balance. Scores will be compared pre- vs post- RT.


Recruitment information / eligibility

Status Completed
Enrollment 16
Est. completion date January 31, 2023
Est. primary completion date January 26, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Males and females =18 years of age - Fluent in written and spoken English - Must be able to provide and understand informed consent - Must have an ECOG PS of = 2 - Diagnosed with metastatic disease - Cancer patients (stage 1-4) - Treatment to primary site or metastatic disease - Scheduled to receive radiation therapy at Penn State Cancer Institute - Absence of absolute contraindications for exercise according to the American Heart Association (see below) - Primary attending oncologist approval - Receiving treatment as an outpatient Exclusion Criteria: - Receiving radiation therapy at a location other than Penn State Cancer Institute - Not fluent in written and spoken English - Evidence in the medical record of an absolute contraindication for exercise - Performing > 90 minutes/week of physical activity at the time of initial evaluation - Cardiac exclusion criteria: - Class II, III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system - History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty or stenting within the past 6 months prior to the start of radiation therapy - Uncontrolled arrhythmias; patients with rate controlled atrial fibrillation for >1 month prior to start of radiation therapy may be eligible - syncope - acute myocarditis, pericarditis, or endocarditis - acute pulmonary embolus or pulmonary infarction - thrombosis of lower extremities - suspected dissecting aneurysm - pulmonary edema - respiratory failure - acute non-cardiopulmonary disorder that may affect exercise performance or be aggravated by exercise - mental impairment leading to inability to cooperate - Pregnant women - In-patient receiving radiation therapy for a radiation emergency (e.g. cord compression, SVC syndrome, brain metastases) - High risk of fracture or spine instability (Mirels score =7, SINS =7) - Children (the protocol will only include individuals 18 and older)

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise Therapy
Certified exercise oncology specialists will personalize, prescribe, and guide ET, including twice weekly resistance training and walking, performed at home, with supervision in the Exercise Medicine Unit. The cancer exercise physiologist will teach participants proper warm ups, use of equipment, exercise form, modes of activity, intensity of exercise, flexibility exercises, and cool down. In addition, patients will be instructed to exercise on their own, at home, according to the instructions from the cancer exercise specialist.

Locations

Country Name City State
United States Penn State Cancer Institute Hershey Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Milton S. Hershey Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptability of exercise intervention: (number of patients agreeing to perform RT+ET)/(number approached) (number of patients agreeing to perform RT+ET)/(number approached) 1 year
Primary Feasibility of exercise intervention: (number of patients who completed RT+ET)/(number agreeing to perform RT+ET) (number of patients who completed RT+ET)/(number agreeing to perform RT+ET) 1 year
Primary Incidence of Treatment- Emergent Adverse Events Safety of exercise intervention: freedom from any Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher event 1 year
Secondary Change in timed up and go Timed up and go 3 Months
Secondary change in grip strength Grip strength 3 Months
Secondary change in quality of life measured via the Godin Physical Activity Questionnaire The Godin Physical Activity Questionnaire asks how much physical activity the participant engages in during a typical 7-day period. 3 Months
Secondary change in quality of life measured via the Barriers to Exercise RM 5-FM survey The Barriers to Exercise RM 5-FM survey asks participants about barriers to being active. Response options include: very likely; somewhat likely; somewhat unlikely; very unlikely. 3 Months
Secondary change in quality of life measured via the Work Productivity and Activity Impairment Questionnaire The Work Productivity and Activity Impairment Questionnaire ask about the effect of the participant's health problems on the ability to work and perform regular activities. A variety of question/response styles are included in the survey. 3 Months
Secondary change in quality of life measured via the Scored Patient-Generated Subjective Global Assessment The Score Patient-Generated Subjective Global Assessment asks about participant nutrition. A variety of question/response styles are included in the survey. 3 Months
Secondary change in quality of life measured via the EORTC questionnaire The EORTC Quality of life questionnaire asks a variety of questions about their health regarding physical abilities. Response options include: not at all; a little; quite a bit; very much. 3 Months
Secondary change in quality of life measured via the ECHO EXERT survey The Experience of Care and Health Outcomes (ECHO) Survey asks three questions about participant experience with the exercise intervention. Response options include: not at all; not much; mixed; somewhat; very much so. 3 Months
Secondary change in quality of life measured via the Health Belief Scale The Health Belief Scale asks questions regarding exercise therapy. Response options include: strongly disagree - strongly agree, where 1 equals strongly disagree and 4 equals strongly agree. 3 Months
See also
  Status Clinical Trial Phase
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Recruiting NCT05798611 - Study of ART0380 in Patients With Biologically Selected Solid Tumors Phase 2
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT05566574 - A Study of RP-3500 in Combination With Standard Radiation Therapy in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05036681 - A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma Phase 2
Withdrawn NCT00005030 - SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver Phase 1
Recruiting NCT05525858 - KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
Recruiting NCT04085029 - Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Recruiting NCT06058988 - Trastuzumab Deruxtecan (T-DXd) for People With Brain Cancer Phase 2
Not yet recruiting NCT05981170 - Rurality Adapted Physical Activity Sport Health
Not yet recruiting NCT03058809 - Evaluation of Viatarâ„¢ Oncopheresis System in Removing CTC From Whole Blood Phase 1/Phase 2
Completed NCT02529553 - A Study of LY3076226 in Participants With Advanced or Metastatic Cancer Phase 1
Terminated NCT01929941 - An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies Phase 1
Completed NCT01302808 - Romidepsin and Erlotinib Hydrochloride in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Phase 1
Terminated NCT00918645 - Calcium-41 (41Ca) Chloride Aqueous Solution in Diagnosing Patients With Prostate Cancer and Bone Metastasis N/A
Completed NCT00795678 - Chemotherapeutic Agents in Brain/Breast N/A
Withdrawn NCT00769990 - Genistein in Treating Patients Undergoing External-Beam Radiation Therapy for Bone Metastases Phase 1/Phase 2
Completed NCT00557102 - Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung Phase 2
Recruiting NCT00398437 - Magnetic Resonance Imaging for the Early Detection of CNS Metastases in Women With Stage IV Breast Cancer N/A